Figure 3.

Cdr1as Enhances the Cisplatin Chemosensitivity of Ovarian Cancer In Vivo

(A) Volume of tumors that developed in xenografts from different groups. (B) Weights of tumors that developed in xenografts from different groups. The group settings are as follows: group 1, sh-Cdr1as-transfected cells + cisplatin; group 2, sh-Cdr1as-transfected cells + NS; group 3, sh-NC-transfected cells + cisplatin; and group 4, sh-NC-transfected cells + NS. All tests were performed at least three times. **p < 0.01 compared with respective groups. (C) The percentage of KI67-positive cells in xenografts from different groups. All tests were performed at least three times. Data were expressed as mean ± SD. **p < 0.01.